ABSTRACT
INTRODUCTION
The role of these antibodies in cytopenias is far less well defined than that of thrombosis. It has been suggested that the binding of these antibodies to phospholipids in platelet membrane can lead to platelet activation and aggregation'" thus leading possibly to thrombocytopenia. In addition, this process might also enhance platelet destruction by the reticuloendothelial system causing further cytopenia. A similar mechanism may occur in immune haemolytic anaemia.
DETECTION OF ANCIPHOSPIIOLIPID ANTIBODIES
The first antiphospholiptd antibody to be detected is the lupus anticoagulant, demonstrated by a prolongation of the partial thromboplastin time(PTT) or kaolin clotting time(KCT), and not correctable by the addition of normal plasmaf301. The subsequent development of a sensitive ELISA method using cardiolipin as antigen to detect anticardiolipin antibodies gave a boost to the routine detection of these antibodies. In addition it enabled the detection of ACA isotypes(IgG, IgM, IgA). However certain points need to be borne in mind. Studies using affinity purified ACA show that a plasma protein cofactor ìs necessary for binding to liposomes and characterisation of this co -factor show that it closely resembles beta,-glycoprotein I (apolipoprotein H)(J1. Heat treatment of antiphospholipid antibody -negative serum or plasma samples for as short as 30 min at 56°C to inactivate complement activity can cause a false positive resultt3R). The Venereal Disease Reference Laboratory(VDRL) test is another serological test for the presence of antiphospholipid antibodies. This test contains both cardiotipin and phosphatidylcholine as antigens. This is a biological false -positive result because all these patients gave negative results when tested with more specific tests for syphilis eg Treponema Pallidium Haemagglutination test (fPHA). There are reported correlations between different populations of antibodies assayed by the various laboratory tests but not total concordance, thus indicating the existence of overlapping groups of antibodies.
MANAGEMENT OF APS
The present medical management of the antiphospholipid syndrome consists of the use of immunosuppressives, platelet inhibitors and anticoagulants, singly or in combination. The basis for using corticosteroids is to suppress antiphospholipid antibody activity("). However there is no convincing evidence that this is actually the case as ACA levels can remain high despite high dose corticosteroid treatmentt3a'. The optimal dose of corticostcroids to be used is unknown although a daily dose of 40 mg to 60 mg of prednisolone has been recommended for recurrent aborters ie those with more than two spontaneous abortions"J93. The potential benefits of such a therapy may not outweigh the potential side effects of preeclampsia, foetal growth retardation and prematurity. The heightened awareness of the role that ACA play in recurrent aborters has resulted in more careful ante -natal care and regular foetal monitoring. These factors contribute significantly to successful pregnancies.
Low dose aspirin can selectively inhibit thromboxane A, synthesis and theoretically can prevent occlusion of small vessels. Subcutaneous heparin have been used successfully in recurrent aborterst361. However the use of low dose aspirin and subcutaneous low molecular weight heparin as a standard treatment for recurrent spontaneous abortions is still the subject of ongoing therapeutic trials.
Long term anticoagulation with warfarin in patients with high levels of these antibodies and a history of recurrent strokes or venous thrombosis has been proposed by somet37l. The use of anti -platelet agents has not been proven to be definitely effective in treating the cerebrovascular features of this syndrome. In addition, corticosteroids use did not prevent recurrences of stroke or the onset of nulltistroke dementia and its use should be limited to those with an associated connective tissue disorder.
Hydroxychloroquine has been shown to have an inhibitory effect on phospholipase A, and therefore can affect platelet adhesion One study suggested that hydroxychloroquìne may prevent thromboembol is eventst3Sl, It is therefore a potentially useful drug and controlled trials are needed to delineate its efficacy.
Ongoing controlled clinical trials and basic research into the underlying pathophysiology of the antiphospholipid antibodies promise more answers in the management of this fascinating condition.
